Landscape of systemic therapy for ovarian cancer in 2019: Primary therapy

Keiichi Fujiwara, Kosei Hasegawa, Shoji Nagao

Research output: Contribution to journalReview articlepeer-review

17 Citations (Scopus)

Abstract

According to the statement from the 5th Ovarian Cancer Consensus Conference in 2015, the primary systemic chemotherapy for advanced ovarian cancer is a combination of paclitaxel plus carboplatin administered every 3 weeks (PCq3w). Optional alternatives include weekly dose-dense paclitaxel, in combination and maintenance therapy with bevacizumab, and intraperitoneal chemotherapy. Since then, in addition to the PCq3w strategy, there has been emerging new evidence, especially for poly(adenosine diphosphate–ribose) polymerase inhibitors. Moreover, there are multiple randomized, phase 3 trials testing the addition of antiangiogenic and/or immune checkpoint inhibitors in this patient population. In this article, current and future perspectives of systemic chemotherapy for advanced ovarian cancer are discussed.

Original languageEnglish
Pages (from-to)4582-4586
Number of pages5
JournalCancer
Volume125
Issue numberS24
DOIs
Publication statusPublished - Dec 15 2019
Externally publishedYes

Keywords

  • antiangiogenic
  • carboplatin
  • intraperitoneal chemotherapy
  • ovarian cancer
  • paclitaxel
  • poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitor
  • primary chemotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Landscape of systemic therapy for ovarian cancer in 2019: Primary therapy'. Together they form a unique fingerprint.

Cite this